IONSNasdaqPharmaceutical PreparationsFiscal year ends December 31
IONIS PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$44.38+1.44 (+3.35%)
Close on Oct 19, 2026
- Market cap
- $7.34B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$28.71 (−39.28%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
IONIS PHARMACEUTICALS INC saw revenue fall 7.4% to $874.09M over the twelve months to Jun 30, 2026. Free cash flow was -$560.84M.
Revenue
$874.09M
-7.4% vs. a year earlier
Operating income
-$594.36M
TTM Q2 2026
Free cash flow
-$560.84M
TTM Q2 2026
EPS, diluted
-$3.46
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $7.34B
- P/E ratio
- –
- Price to sales
- 8.40
- Price to book
- 16.69
- Dividend yield
- –
- Free cash flow yield
- -7.64%
Fundamentals
- Revenue
- $874.09M
- Net income
- -$565.17M
- EPS, diluted
- -$3.46
- Free cash flow
- -$560.84M
- Book value per share
- $2.66
- Diluted shares
- 165M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$874.09M-7.4% YoY
Gross profit
$858.07M-8.1% YoY
Operating income
-$594.36M
Net income
-$565.17M
EPS, diluted
-$3.46
Free cash flow
-$560.84M
Reported periodTrailing twelve months